Cargando…
Hemoadsorption Treatment with CytoSorb® in Probable Hemophagocytic Lymphohistiocytosis: A Role as Adjunctive Therapy?
Acute hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease, with an annual incidence of 1 : 800,000 people. The disease is characterized by a cytokine storm, with concomitant macrophage and natural killer (NK) cell activation; death can occur from multiple organ failure or complica...
Autores principales: | Ceruti, Samuele, Glotta, Andrea, Adamson, Harriet, Mauri, Romano, Molnar, Zsolt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403039/ https://www.ncbi.nlm.nih.gov/pubmed/34462671 http://dx.doi.org/10.1155/2021/5539126 |
Ejemplares similares
-
Hemoadsorption by CytoSorb in septic patients: a case series
por: Kogelmann, Klaus, et al.
Publicado: (2017) -
Experience with hemoadsorption (CytoSorb(®)) in the management of septic shock patients
por: Mehta, Yatin, et al.
Publicado: (2020) -
Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption
por: Schneider, Antoine G., et al.
Publicado: (2021) -
Hemoadsorption in the critically ill—Final results of the International CytoSorb Registry
por: Hawchar, Fatime, et al.
Publicado: (2022) -
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' response
por: Supady, Alexander, et al.
Publicado: (2021)